Information Provided By:
Fly News Breaks for July 20, 2017
JNJ
Jul 20, 2017 | 06:18 EDT
Credit Suisse analyst Vamil Divan reinstated coverage of Johnson & Johnson with an Outperform rating and $148 price target following the close of the Actelion acquisition. The analyst sees "opportunities for significant upside" from assets such as Xarelto, Darzalex and Imbruvica. He believes J&J shares have further room to run.
News For JNJ From the Last 2 Days
JNJ
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
JNJ
Mar 28, 2024 | 13:57 EDT
Johnson & Johnson will pay $75M to settle a consumer protection lawsuit filed by Mississippi over the company's talc-based baby powder, according to people familiar with the matter, resolving litigation in which the state had sought as much as $6B, Bloomberg News' Jef Feeley reports. The pact comes as lawyers for the state and J&J were gearing up for a non-jury trial next month in Jackson, Mississippi, said the people. Mississippi was one of only two states to file suit over J&J's marketing of its baby powder, the author notes. Reference Link
JNJ
Mar 26, 2024 | 16:25 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here